LONDON, June 9, 2026 /PRNewswire/ -- The "Automated People Mover Market – Growth, Share, Opportunities & Competitive Analysis, 2025 – 2032" report has been added...
New Program Connects Biotech and Pharmaceutical Partners with Einstein's Aging Research Expertise and Scientific Infrastructure BRONX, N.Y., June 9, 2026 /PRNewswire/ -- Albert Einstein...
NYON, Switzerland, June 9, 2026 /CNW/ -- As part of its commitment to scientific research, innovation and heritage preservation, Hublot has partnered with Swiss...
STOCKHOLM, June 9, 2026 /PRNewswire/ -- CheckProof, the operations management platform built for construction materials and heavy industry, today published 'Mind the Gap: A Construction...
New Harris Poll research of more than 3,000 U.S. adults finds Eagle Scouts report 2x lower loneliness, significantly higher purpose and leadership and stronger...
- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham
- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma
- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers
VANCOUVER, BC, June 9, 2026 /PRNewswire/ - Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) ("Trilogy Metals", "Trilogy" or the "Company") announced today that field...
VANCOUVER, BC, June 9, 2026 /CNW/ - Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) ("Trilogy Metals", "Trilogy" or the "Company") announced today that field...
HAIKOU, China, June 9, 2026 /PRNewswire/ -- A news report from chinadaily.com.cn:The Hainan Payment Service Electronic Map is now online! Whether you're in Hainan for...
New Jabra study finds that bad meeting culture is costing businesses millions in wasted time, tech failures and downstream work that bad meetings generate.